TACSTD2 and urothelial carcinoma: In 2021, Sacituzumab govitecan, a humanized anti-TROP2 SN-38 monoclonal antibody conjugate, was approved by the U.S. Food and Drug Administration (FDA) for the third-line treatment of patients with metastatic triple-negative breast cancer (TNBC) and urothelial carcinoma [30,31].